These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36377586)

  • 1. Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients.
    Calderón-Goercke M; Loricera J; Moriano C; Castañeda S; Narváez J; Aldasoro V; Maiz O; Melero R; Villa JI; Vela P; Romero-Yuste S; Callejas JL; de Miguel E; Galíndez-Agirregoikoa E; Sivera F; Fernández-López JC; Galisteo C; Ferraz-Amaro I; Sanchéz-Martín J; Sánchez-Bilbao L; González-Gay MA; Hernández JL; Blanco R;
    Clin Exp Rheumatol; 2023 Apr; 41(4):829-836. PubMed ID: 36377586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis-study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study.
    Kreis L; Dejaco C; Schmidt WA; Németh R; Venhoff N; Schäfer VS
    Trials; 2024 Jan; 25(1):56. PubMed ID: 38225579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice.
    Calderón-Goercke M; Castañeda S; Aldasoro V; Villa I; Prieto-Peña D; Atienza-Mateo B; Patiño E; Moriano C; Romero-Yuste S; Narváez J; Gómez-Arango C; Pérez-Pampín E; Melero R; Becerra-Fernández E; Revenga M; Álvarez-Rivas N; Galisteo C; Sivera F; Olivé-Marqués A; Álvarez Del Buergo M; Marena-Rojas L; Fernández-López C; Navarro F; Raya E; Galindez-Agirregoikoa E; Arca B; Solans-Laqué R; Conesa A; Hidalgo C; Vázquez C; Román-Ivorra JA; Loricera J; Lluch P; Manrique-Arija S; Vela P; De Miguel E; Torres-Martín C; Nieto JC; Ordas-Calvo C; Salgado-Pérez E; Luna-Gomez C; Toyos-Sáenz de Miera FJ; Fernández-Llanio N; García A; Larena C; González-Vela C; Corrales A; Varela-García M; Aurrecoechea E; Dos Santos R; García-Manzanares Á; Ortego N; Fernández S; Ortiz-Sanjuán F; Corteguera M; Hernández JL; González-Gay MÁ; Blanco R
    Clin Exp Rheumatol; 2020; 38 Suppl 124(2):112-119. PubMed ID: 32441643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations.
    Unizony S; McCulley TJ; Spiera R; Pei J; Sidiropoulos PN; Best JH; Birchwood C; Pavlov A; Stone JH
    Arthritis Res Ther; 2021 Jan; 23(1):8. PubMed ID: 33407817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension.
    Stone JH; Spotswood H; Unizony SH; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Spiera R; Bao M
    Rheumatology (Oxford); 2022 Jul; 61(7):2915-2922. PubMed ID: 34718434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.
    Calderón-Goercke M; Loricera J; Aldasoro V; Castañeda S; Villa I; Humbría A; Moriano C; Romero-Yuste S; Narváez J; Gómez-Arango C; Pérez-Pampín E; Melero R; Becerra-Fernández E; Revenga M; Álvarez-Rivas N; Galisteo C; Sivera F; Olivé-Marqués A; Álvarez Del Buergo M; Marena-Rojas L; Fernández-López C; Navarro F; Raya E; Galindez-Agirregoikoa E; Arca B; Solans-Laqué R; Conesa A; Hidalgo C; Vázquez C; Román-Ivorra JA; Lluch P; Manrique-Arija S; Vela P; De Miguel E; Torres-Martín C; Nieto JC; Ordas-Calvo C; Salgado-Pérez E; Luna-Gomez C; Toyos-Sáenz de Miera FJ; Fernández-Llanio N; García A; Larena C; Palmou-Fontana N; Calvo-Río V; Prieto-Peña D; González-Vela C; Corrales A; Varela-García M; Aurrecoechea E; Dos Santos R; García-Manzanares Á; Ortego N; Fernández S; Ortiz-Sanjuán F; Corteguera M; Hernández JL; González-Gay MÁ; Blanco R
    Semin Arthritis Rheum; 2019 Aug; 49(1):126-135. PubMed ID: 30655091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study.
    Schmitt C; Brockwell L; Giraudon M; Zucchetto M; Christ L; Bannert B; Daikeler T; Villiger PM
    Arthritis Res Ther; 2022 Jun; 24(1):133. PubMed ID: 35659282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab in giant cell arteritis: an update for the clinician.
    Ford JA; Gewurz D; Gewurz-Singer O
    Curr Opin Rheumatol; 2023 May; 35(3):135-140. PubMed ID: 36912060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicentre, large-scale, observational study of tocilizumab in patients with giant cell arteritis in Japan.
    Harigai M; Miyamae T; Hashimoto H; Umetsu K; Yamashita K; Nakaoka Y
    Mod Rheumatol; 2024 Jul; 34(4):775-783. PubMed ID: 37522620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world Risk of Relapse of Giant Cell Arteritis Treated With Tocilizumab: A Retrospective Analysis of 43 Patients.
    Clément J; Duffau P; Constans J; Schaeverbeke T; Viallard JF; Barcat D; Vernhes JP; Sailler L; Bonnet F
    J Rheumatol; 2021 Sep; 48(9):1435-1441. PubMed ID: 33589561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial.
    Spiera R; Unizony SH; Bao M; Luder Y; Han J; Pavlov A; Stone JH
    Semin Arthritis Rheum; 2021 Apr; 51(2):469-476. PubMed ID: 33784598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study.
    Samson M; Devilliers H; Ly KH; Maurier F; Bienvenu B; Terrier B; Charles P; Guillevin L; Besancenot JF; Liozon E; Fauchais AL; Loffroy R; Binquet C; Audia S; Seror R; Mariette X; Bonnotte B
    Eur J Intern Med; 2018 Nov; 57():96-104. PubMed ID: 30054122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab, an effective treatment for relapsing giant cell arteritis.
    Oliveira F; Butendieck RR; Ginsburg WW; Parikh K; Abril A
    Clin Exp Rheumatol; 2014; 32(3 Suppl 82):S76-8. PubMed ID: 24854376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab in Giant Cell Arteritis: A Real-Life Retrospective Study.
    Vitiello G; Orsi Battaglini C; Carli G; Radice A; Matucci A; Vultaggio A; Olianti C; Parronchi P; Maggi E; Cammelli D
    Angiology; 2018 Oct; 69(9):763-769. PubMed ID: 29343075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial.
    Strand V; Dimonaco S; Tuckwell K; Klearman M; Collinson N; Stone JH
    Arthritis Res Ther; 2019 Feb; 21(1):64. PubMed ID: 30786937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.
    Unizony S; Arias-Urdaneta L; Miloslavsky E; Arvikar S; Khosroshahi A; Keroack B; Stone JR; Stone JH
    Arthritis Care Res (Hoboken); 2012 Nov; 64(11):1720-9. PubMed ID: 22674883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis.
    Conticini E; Sota J; Falsetti P; Baldi C; Bardelli M; Bellisai F; Tosi GM; Frediani B; Cantarini L
    Mediators Inflamm; 2020; 2020():3203241. PubMed ID: 33061825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients.
    Loricera J; Blanco R; Hernández JL; Castañeda S; Mera A; Pérez-Pampín E; Peiró E; Humbría A; Calvo-Alén J; Aurrecoechea E; Narváez J; Sánchez-Andrade A; Vela P; Díez E; Mata C; Lluch P; Moll C; Hernández Í; Calvo-Río V; Ortiz-Sanjuán F; González-Vela C; Pina T; González-Gay MÁ
    Semin Arthritis Rheum; 2015 Jun; 44(6):717-23. PubMed ID: 25697557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse Risk and Safety of Long-Term Tocilizumab Use Among Patients With Giant Cell Arteritis: A Single-Enterprise Cohort Study.
    Samec MJ; Rakholiya J; Langenfeld H; Crowson CS; Abril A; Wang B; Mertz L; Rodriguez-Pla A; Bansal P; Burke M; Jaquith J; Weyand C; Warrington KJ; Koster MJ
    J Rheumatol; 2023 Oct; 50(10):1310-1317. PubMed ID: 37321636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.
    Régent A; Redeker S; Deroux A; Kieffer P; Ly KH; Dougados M; Liozon E; Larroche C; Guillevin L; Bouillet L; Espitia O; Costedoat-Chalumeau N; Soubrier M; Brihaye B; Lifermann F; Lefevre G; Puéchal X; Mouthon L; Toussirot E;
    J Rheumatol; 2016 Aug; 43(8):1547-52. PubMed ID: 27182063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.